- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Hope Rugo, MD | Authors
Hope S. Rugo, MD, Talks Aromatase Inhibitors Plus Ribociclib in HR+/HER2– Advanced Breast Cancer
July 25, 2022
Hope S. Rugo, MD, FASCO, gave an overview of ribociclib plus aromatase inhibitor use vs abemaciclib plus aromatase inhibitors for patients with hormone receptor-positive, HER2-negative advanced breast cancer.
Hope S. Rugo, MD, on Comparing CDK4/6 Inhibitors in HR+/HER2– Advanced Breast Cancer
July 24, 2022
Hope S. Rugo, MD, FASCO, reviewed data from a matching-adjusted indirect comparison study which analyzed quality of life in patients with hormone receptor–positive, HER2-negative advanced breast cancer treated with ribociclib- or abemaciclib-based regimens.
Hope S. Rugo, MD, Discusses Future Analyses of Sacituzumab Govitecan in HR+/HER2– Advanced Breast Cancer at ASCO 2022
June 14, 2022
Hope S. Rugo, MD, FASCO, spoke about future analyses of the phase 3 TROPiCS-02 trial that examined sacituzumab govitecan vs physicians’ choice chemotherapy in patients with hormone receptor–positive, HER2-negative advanced breast cancer.
Hope S. Rugo, MD, FASCO, Reviews TROPiCS-02 Trial Data in HR+/HER2– Advanced Breast Cancer at 2022 ASCO
June 09, 2022
Hope S. Rugo, MD, spoke about results of the phase 3 TROPiCS-02 trial examining sacituzumab govitecan vs physicians’ choice chemotherapy for patients with hormone receptor–positive, HER2-negative advanced breast cancer presented at ASCO 2022.
Hope Rugo, MD, On the Future of Breast Cancer Treatment
March 12, 2020
The breast oncologist from the University of California, San Francisco, discussed new agents being developed in the breast cancer space.